AMISULPRIDE causes QT prolongation. Avoid use of AMISULPRIDE in patients taking droperidol to avoid potential additive effects.
Source: NLP:amisulpride
Brand names: Barhemsys
Dopamine-2 Receptor Antagonist · Dopamine D2 Antagonists
Route: Intravenous
Contraindications
4 CONTRAINDICATIONS BARHEMSYS is contraindicated in patients with known hypersensitivity to amisulpride [see Adverse Reactions (6.2) ] . Known hypersensitivity to amisulpride. ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary Available data with amisulpride use in pregnant women are insufficient to establish a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, there were no adverse developmental effects observed with oral administration of amisulpride in rats and rabbits during the period of organogenesis at exposures about 43 and 645 times, respectively, the exposure delivered by the highest recommended human dose (see Data ) . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Reproduction studies of amisulpride were conducted in pregnant rats administered oral doses up to 160 mg/kg/day (43 times the exposure based on area under the curve (AUC) at the highest recommended dose of 10 mg) throughout the period of organogenesis. No adverse embryo-fetal developmental effects were observed at any dose level. Maternal animals exhibited a dose-related decrease in overall mean body weight gain. In rabbits administered amisulpride throughout the period of organogenesis, oral doses up to 210 mg/kg/day (645 times the exposure based on AUC at the highest recommended dose of 10 mg) had no adverse developmental effects on the fetus. Maternal animals exhibited reduced mean body weight gain at doses of 100 and 210 mg/kg/day and reduced food intake was observed at 210 mg/kg/day. The pre- and post-natal developmental effects of amisulpride were assessed in rats administered oral doses of 60, 100 or 160 mg/kg/day during the periods of organogenesis and lactation. At 160 mg/kg/day (43 times the exposure based on AUC at the highest recommended dose of 10 mg), materna
3 interactions on record
AMISULPRIDE causes QT prolongation. Avoid use of AMISULPRIDE in patients taking droperidol to avoid potential additive effects.
Source: NLP:amisulpride
Reciprocal antagonism of effects occurs between dopamine agonists and AMISULPRIDE. Avoid using levodopa with AMISULPRIDE.
Source: NLP:amisulpride
Ondansetron is known to prolong QT interval; ECG monitoring recommended when used with amisulpride.
Source: NLP:amisulpride